
Cleveland Clinic Taussig Cancer Institute
Taussig Cancer Institute is the hub for Cleveland Clinic Cancer Center.
- 2023 Breast Cancer Update: Review of Breast Cancer Symposia
- 2023 Management of Checkpoint Inhibitor-Related Toxicity
- 2022 Management of Checkpoint Inhibitor-Related Toxicities
- 2022 Breast Cancer Update: Review of Breast Cancer Symposium
- 2021 Management of Checkpoint Inhibitor-Related Toxicity
- Breast Cancer Update: Review of Breast Cancer Symposia
- 7th Annual Multidisciplinary Colorectal Oncology Course
- ASCO 2020 Highlights
- 20th Annual ASH Review
- 2020 Management of Checkpoint Inhibitor-Related Toxicity
- 2020 Multidisciplinary Head and Neck Cancer Update
- 6th Annual Multidisciplinary Colorectal Oncology Course
- 5th Annual Cleveland Breast Cancer Summit
- 5th Annual Multidisciplinary Colorectal Oncology Course
- Breast
- GI
- GU
- Skin
- Lymphoma
- Leukemia
- Lung
- Gyn
- MDS/MPN
- Benign Hematology
- Myeloma
- Hematologic Malignancies
- Events
- Updates in Melanoma and High Risk Skin Cancer Management
Playback speed
10 seconds
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
2019 ASH Review on R/R DLBCL: For Frail Unfit Patients, Addition of Polatuzumab Vedotin to BR Is Tolerable and Improves ORR, CR, PFS and OS
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Brian Hill
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Brian Hill
0 views
April 14, 2020
Comments 0
Login to view comments.
Click here to Login
Malignant Hematology